Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
On exclusivity, it is a good point to make that exclusivity may come in different forms. The most likely, IMO, is in the application of the antibody eg the combination with CPI.
Look out for patent-extending potential…?
Interesting to have five companies all looking for exclusivity etc. No wonder at least 1-2 deals expected this year. That will also extend the cash runway and/or will allow to move further along with development before partnering. And then there is the Q of milestone payments from GenMab……
If you wish. I went on this a few weeks ago….
https://puffingbilly.com.au/
……plenty of twist and turns, pretty slow progress, occasional great views, seemed to go on quite a long time despite completely stopping occasionally……but got there in the end.
I see it more like a funicular railway, in which there are frequent hiatuses in an ascent, leaving passengers with the opportunity to get out, twiddle their thumbs and admire the view. Those who get off for such purposes need to remember to get back on again…..
Ruck is correct. This RNS (whilst welcome and prompt) is not a dial-shifter. It merely confirms what we were told to expect in November really.
They’ve hired a professional sector-focused set of advisers - they know what they are doing and, when game-changing news turns up, I’m sure it won’t be undersold.
….talking of valuations…..
https://www.telegraph.co.uk/business/2024/01/18/wall-street-raiders-battling-control-smart-meters/
Nobody can control whether MHRA sign-offs happen on a good day or a bad day. News needs to be released promptly when it happens.
I’d settle for the next trial results being on a day when institutions or industry players are actively looking out for “the next big thing” - and breaking out above 30p on the back of it.
The word “exceptional” is important - because it completely explains why MHRA has been helpfully expediting approvals.
It may be worth remembering Chancellor Jeremy Hunt’s comment last year:
“ And with an extra £10m of funding over the next two years they (the MHRA) will put in place the quickest, simplest, regulatory approval in the world for companies seeking rapid market access.”
Well at least this promptly validates the point in the November RNS:
“ Scancell has also received MHRA correspondence requesting a preclinical mouse safety study with iSCIB1+ prior to resubmission of the amendment to the current trial protocol to include a new parallel cohort with the double CPIs with iSCIB1+. Management do not see any potential issue with this regulatory request having previously completed identical studies with SCIB1. The iSCIB1+ cohort is now expected to start in Q1 2024.”
It does appear that the MHRA are indeed being responsive……which is both helpful and somewhat intriguing….
Https://www.lse.co.uk/rns/SCLP/update-on-scope-trial-xyrhx622822790d.html
Due imminently, I think. News re Vietnam will feature - but what?